• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Chudnovsky Yekaterina bought $7,047,530 worth of shares (1,213,000 units at $5.81) (SEC Form 4)

    12/26/23 4:29:30 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANGN alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Chudnovsky Yekaterina

    (Last) (First) (Middle)
    C/O ELICIO THERAPEUTICS, INC.
    451 D STREET, 5TH FLOOR, SUITE 501

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Elicio Therapeutics, Inc. [ ELTX ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    12/22/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 12/22/2023 P 1,213,000 A $5.81 1,915,639 I Held by GKCC, LLC(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    Chudnovsky Yekaterina

    (Last) (First) (Middle)
    C/O ELICIO THERAPEUTICS, INC.
    451 D STREET, 5TH FLOOR, SUITE 501

    (Street)
    BOSTON MA 02210

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    GKCC, LLC

    (Last) (First) (Middle)
    501 SILVERSIDE ROAD, SUITE 87AVA

    (Street)
    WILMINGTON DE 19809

    (City) (State) (Zip)
    Explanation of Responses:
    1. Yekaterina (Katie) Chudnovsky is the sole member and manager of GKCC, LLC and may be deemed to beneficially own the shares held by GKCC, LLC.
    Remarks:
    /s/ Yekaterina Chudnovsky 12/26/2023
    /s/ Yekaterina Chudnovsky, Manager of GKCC, LLC 12/26/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ANGN alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANGN

    DatePrice TargetRatingAnalyst
    12/10/2021$15.00 → $8.00Outperform
    Oppenheimer
    11/9/2021$100.00 → $50.00Buy
    HC Wainwright & Co.
    10/27/2021$40.00 → $15.00Buy
    Stifel
    More analyst ratings

    $ANGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Demuth Peter

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/5/24 6:01:39 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Haqq Christopher

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/5/24 6:01:41 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Piekos Brian

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    2/5/24 6:01:51 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Angion Biomedia Corp. Announces 1-for-10 Reverse Stock Split

    NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-10. Angion's common stock will begin trading on a split-adjusted basis when the market opens on June 2, 2023 under the new trading symbol "ELTX." As a result of the reverse stock split, the CUSIP number for Angion's common stock will now be 28657F103. The reverse stock split was previously approved by the stockholders of Ang

    6/1/23 8:00:00 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Elicio Therapeutics and Angion Enter into Definitive Merger Agreement

    Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio's proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern Time on Wednesday, January 18 BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entere

    1/17/23 5:00:00 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion Receives Nasdaq Notice Regarding Minimum Bid Price Requirements

    UNIONDALE, N.Y., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, announced that on December 15, 2022, it received a letter from the Nasdaq Listing Qualifications Staff of The Nasdaq Stock Market notifying Angion that for the last 30 consecutive business days the bid price of Angion's common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requirements of Nasdaq listing rule 5450(a)(1). The notification received has no immediate effect on the listin

    12/21/22 9:50:00 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGN
    SEC Filings

    View All

    Angion Biomedica Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

    2/2/24 8:51:10 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion Biomedica Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

    1/17/24 8:35:57 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion Biomedica Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Elicio Therapeutics, Inc. (0001601485) (Filer)

    1/16/24 7:59:58 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chudnovsky Yekaterina bought $7,047,530 worth of shares (1,213,000 units at $5.81) (SEC Form 4)

    4 - Elicio Therapeutics, Inc. (0001601485) (Issuer)

    12/26/23 4:29:30 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Oppenheimer reiterated coverage on Angion Biomedica with a new price target

    Oppenheimer reiterated coverage of Angion Biomedica with a rating of Outperform and set a new price target of $8.00 from $15.00 previously

    12/10/21 7:18:08 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. reiterated coverage on Angion Biomedica with a new price target

    HC Wainwright & Co. reiterated coverage of Angion Biomedica with a rating of Buy and set a new price target of $50.00 from $100.00 previously

    11/9/21 7:47:50 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel reiterated coverage on Angion Biomedica with a new price target

    Stifel reiterated coverage of Angion Biomedica with a rating of Buy and set a new price target of $15.00 from $40.00 previously

    10/27/21 8:24:41 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGN
    Financials

    Live finance-specific insights

    View All

    Elicio Therapeutics and Angion Enter into Definitive Merger Agreement

    Merger to result in Nasdaq-listed company focused on developing immunotherapies based on Elicio's proprietary lymph node-targeting Amphiphile (AMP) technologyLead program of the combined company will be ELI-002, a therapeutic cancer vaccine targeting mKRAS-driven tumors, currently enrolling a Phase 1 trial for patients with pancreatic ductal adenocarcinoma and colorectal cancer Conference call to be held 8:00 am Eastern Time on Wednesday, January 18 BOSTON and UNIONDALE, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a privately-held, clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases, has entere

    1/17/23 5:00:00 AM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion and Vifor Pharma Report Topline Results from Phase 2 GUARD Trial of ANG-3777 in Cardiac Surgery-Associated Acute Kidney Injury

    -- Angion to host a conference call today at 4:30 p.m. EST UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced results from the exploratory Phase 2 GUARD trial of Angion's ANG-3777 in patients undergoing cardiac surgery involving cardiopulmonary bypass at risk for developing acute kidney injury (CSA-AKI). The trial did not meet its primary endpoint of percentage increase in serum creatinine based upon the area under the curve (AUC). However, Angion and Vifor Pharma continue to review the data based on the signal demonstrated in the clinically relevant MAKE90 secondary endpoint. The GU

    12/9/21 4:05:00 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Angion and Vifor Pharma Report Topline Results from Phase 3 Trial of ANG-3777 in Kidney Transplant Patients at Risk for Delayed Graft Function

    UNIONDALE, N.Y. and ST. GALLEN, Switzerland, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN) and Vifor Pharma today announced the Phase 3 trial of Angion's ANG-3777 did not demonstrate a statistically significant difference from placebo on the primary endpoint (eGFR at 12 months) in the population of deceased donor kidney transplant patients who were at risk for developing delayed graft function (DGF). ANG-3777 showed a modest but not statistically significant difference in eGFR of 53.3mL/min/1.73m2 versus 50.4mL/min/1.73m2 for placebo (2.9 mL/min/1.73m2, p=0.33). In addition, ANG-3777 demonstrated an inconsistent benefit on key secondary endpoints. Based upon these

    10/26/21 4:05:00 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Angion Biomedica Corp. (Amendment)

    SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

    12/27/23 4:07:01 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Angion Biomedica Corp. (Amendment)

    SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

    12/26/23 4:25:31 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Angion Biomedica Corp. (Amendment)

    SC 13D/A - Elicio Therapeutics, Inc. (0001601485) (Subject)

    8/30/23 5:16:05 PM ET
    $ANGN
    Biotechnology: Pharmaceutical Preparations
    Health Care